louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05431842: Urdu Version of Functional Gait Assessment Scale: Reliability and Validity Study
Official title: Analysis of Reliability and Validity of Urdu Version of Functional Gait Assessment Scale Among Pakistani Geriatric Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke
Keywords: Functional Gait Assessment Scale
Urdu Version
Reliability
Validity
Stroke
Geriatric Population
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-06-24
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pakistani population post-stroke over the age of 18 years or older.

Brief summary: The aim of study is to translate and culturally adapt Functional Gait Assessment Scale into Urdu language and to investigate the reliability and validity in Pakistani Stroke patients. Also check its correlation with Berg Balance Scale and Barthel Index

Detailed description: The English version of the Functional Gait Assessment Scale will be translated and culturally adapted as per previous recommendation. In geriatric population, Urdu Version of Functional Gait Assessment Scale will distributed among 160 participants choose by convenience sampling technique based on pre-defined inclusion and exclusion criteria.To test inter and intra-observer reliability of the final Urdu Version of Functional Gait Assessment Scale, Barthel Index and Berg Balance Scale, questionnaire will be filled on the same day. Data will be entered and analyzed using Statistical Package of Social Sciences Version 24. Internal consistency will be analyzed with Cronbach alpha value. Test- retest reliability will be assessed for intra-class correlation coefficient. The Urdu Version of Functional Gait Assessment Scale was evaluated for content validity, construct validity, criterion validity and responsiveness.

Eligibility criteria: Inclusion Criteria:

* Age at least 18 years
* Post stroke patients past 3 months
* Both gender patients are included

Exclusion Criteria:

* Patient suffering from any neurological disorder
* Patient suffering from any musculoskeletal disorder
* Patients who are post stroke less than 3 months

Primary outcomes:
measure: Functional Gait Assessment Scale
timeFrame: 1st day
measure: Barthel Index
timeFrame: 1st day
measure: Berg Balance Scale
timeFrame: 1st day
Secondary outcomes:
Other outcomes:
Locations:
city: Faisalabad
country: Pakistan
facility: Ripah International University
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Kashif
role: STUDY_CHAIR
References:
Clinical trial NCT00610142: Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis
Official title: Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atopic Dermatitis
Keywords: atopic dermatitis
pimecrolimus
hydrocortison
Optical Coherence Tomography
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2008-02-07
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: to explore the atrophogenic potentials of hydrocortison 1% cream and pimecrolimus 1% cream on unaffected forehead skin


Eligibility criteria: Inclusion Criteria:

* age 18-60 years
* diagnosis of atopic dermatitis (Hanifin \& Rajka Criteria)
* patients with atopic dermatitis not affecting the forehead

Exclusion Criteria:

* pregnancy / nursing mothers
* women in reproductive age without adequate contraception
* severe atopic dermatitis (IGA \>= 4)
* UV-Therapy in past 4 weeks
* patients receiving any topical treatment on the face in past 6 month

Primary outcomes:
measure: thickness of epidermis
timeFrame: 4 weeks
Secondary outcomes:
measure: thickness of dermis
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Department of Dermatology, Medical Faculty, TU Dresden
Study officials:
affiliation: Department of Dermatology, Medical Faculty, Technical University Dresden, Germany
name: Roland Aschoff, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Aschoff R, Schmitt J, Knuschke P, Koch E, Brautigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011 Oct;20(10):832-6. doi: 10.1111/j.1600-0625.2011.01335.x. Epub 2011 Jul 19.
Clinical trial NCT02621242: Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals
Official title: Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2015-12-03
Enrollment: 9
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is a prospective observational study of cis-gender male persons initiating HIV pre-exposure prophylaxis.

Brief summary: As explained in detail in a recently published hypothesis article (Hladik F. A new hypothesis on HIV cure. F1000Research, 4:77 (2015)), the investigators hypothesize that NRTI drugs may reduce the likelihood of HIV eradication by promoting the survival of cells with integrated provirus. In this study, the investigators will test whether daily oral use of two NTRI drugs, tenofovir and emtricitabine (Truvada Pill), induces changes in the upper and lower gut mucosa that are congruent with supporting this hypothesis.


Eligibility criteria: Inclusion Criteria:

* • HIV-negative

  * Male gender at birth
  * Age ≥18 years old
  * Intent to initiate PrEP in the next 1-2 months.
  * Willingness and ability to provide informed consent for study participation
  * Willingness to undergo all required study procedures

Exclusion Criteria:

* Creatinine clearance \< 60mL/min
* Platelet count below the normal reference
* Coagulation (PT/PTT) tests above the normal reference
* Any prior use of PrEP
* Use of PEP within 30 days prior to study entry
* Receipt of

  * anti-coagulant medications (e.g. warfarin). Aspirin is allowable.
  * Systemic corticosteroid medications
  * Non-steroidal anti-inflammatory drug (NSAID) use \>2 days/week
* Signs or symptoms of acute HIV infection within 14 days of study entry
* No availability of another person who will drive participant home on days of entry and follow-up procedures.
* Plan to leave the Seattle area in the subsequent 2.5 months
* Any condition or substance use that, in the opinion of the study investigator, would interfere with study participation.

Primary outcomes:
measure: Global Transcriptome Analysis
timeFrame: 2-3 months after initiating HIV Pre-exposure prophylaxis
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Harborview Medical Center
state: Washington
Study officials:
affiliation: University of Washington
name: Joanne Stekler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03734042: PRP Intrauterine Infusion in Thawed Embryo Cycles
Official title: Intrauterine Infusion of Platelet-rich Plasma Infusion Before Thawed Embryo Transfer in Repeated Implantation Failure: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Evaluations
Keywords: Platelet rich plasma
Intrauterine infusion
Thawed embryos
IVF/ICSI cycles
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2018-11-07
Enrollment: 102
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 groups parallel
Primary purpose: TREATMENT

Brief summary: All patients prepared to thawed embryo transfer were classified into 2 groups one group will receive platelet rich plasma (PRP) infusion intrauterine and the other group will not receive platelet rich plasma (PRP) infusion

Detailed description: Patients candidates for Thawed embryo transfer with Repeated implantation failure were recruited from 3 centers and classified into 2 groups:

Group I: Will receive platelet rich plasma (PRP) intrauterine infusion at day 11

Group II: Not receiving platelet rich plasma (PRP)

Eligibility criteria: Inclusion Criteria:

* Patients age 20-35 years
* Patients with previous implantation failure
* Patients with thin endometrium\<7 mm

Exclusion Criteria:

* Patients older than 40 years
* Patients with fresh embryo transfer
* Patients with abnormal uterine cavity septate, or bicornuate uterus
* Patients with abnormal male factor or tubal factor
* Patients with abnormal embryos grade B or C.
* Patients with immunological disorders as thyroidits or systemic lupus or rheumatoid arthritis

Primary outcomes:
measure: Endometrial thickness
timeFrame: 8 days
measure: Pregnancy rate
timeFrame: 15 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Ayman Shehata Dawood
Study officials:
References:
Clinical trial NCT01459042: Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China
Official title: Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension, Resistant to Conventional Therapy
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2011-10-25
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with resistant hypertension from different provinces of China

Brief summary: Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.


Eligibility criteria: Inclusion Criteria:

* patients with resistant hypertension
* age 18-65 years

Exclusion Criteria:

* known cause of hypertension
* heart failure
* renal dysfunction
* Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
* cirrhosis
* pregnancy
* undertreatment of glucocorticoid

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine
state: Shanghai
Study officials:
affiliation: Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine
name: Weiqing Wang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05983042: Effect of CYP2C9*3 Polymorphism on Ibuprofen in Pakistani Population
Official title: Effect of CYP2C9*3 rs 1057910 Polymorphism on the Efficacy and Tolerability of Ibuprofen After Molar Tooth Extraction in Pakistani Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Volunteers
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-08-09
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals who were advised for molar tooth extractions based on orthodontic, periodontal, and endodontic indications

Brief summary: The goal of this Observational study was to identify the effect of CYP2C9 gene polymorphism in the Pakistani population. The main question it aims to answer were:

* to evaluate the effect of this genetic polymorphism on the clinical efficacy of Ibuprofen
* to evaluate the effect of this genetic polymorphism on the clinical tolerability of Ibuprofen Participants were prescribed Ibuprofen after molar tooth extraction.

Detailed description: The goal of this observational study was to identify the effect of CYP2C9\*3 gene polymorphism in the Pakistani population, due to the high prevalence of this variant in the Pakistani Population

The main question it aims to answer were:

* to evaluate the effect of this genetic polymorphism on the clinical efficacy of Ibuprofen
* to evaluate the effect of this genetic polymorphism on the clinical tolerability of Ibuprofen Participants were prescribed Ibuprofen after molar tooth extraction.

The blood samples of the participants were taken and further genotyping was performed using conventional tetraARMS PCR. The results were visualized by gel electrophoresis.

Eligibility criteria: Inclusion Criteria:

* Pakistani individuals
* Absence of systemic diseases
* Extractions required based on orthodontic, periodontal, and endodontic indications

Exclusion Criteria:

* history of bleeding or gastrointestinal ulcers
* allergic to ibuprofen or other NSAIDs.
* Pregnancy

Primary outcomes:
measure: To evaluate the genetic variabilities in the clinical efficacy of ibuprofen after molar tooth extraction using a visual analog scale VAS
timeFrame: three days
Secondary outcomes:
measure: To evaluate the genetic variabilities in the tolerability of ibuprofen after molar tooth extraction using the General Assessment of Side Effects GASE scale.
timeFrame: three days
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Ammarah Amjad
state: Punjab
Study officials:
affiliation: Riphah International University
name: Ammarah Amjad, BDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03038542: Quit4hlth: Enhancing Tobacco and Cancer Control Through Framed Text Messages
Official title: Quit4hlth: Enhancing Tobacco and Cancer Control Through Framed Text Messages
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
Collaborators: name: Roswell Park Cancer Institute
First posted: 2017-01-31
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates a text messaging intervention through a smokers' quitline. Smokers will either receive 30 weeks of tailored, gain-framed text messages or 30 weeks of tailored, standard care text messages, both combined with standard quitline treatment. We hypothesize that the gain-framed text message intervention will increase cessation rates at 30 weeks as compared to standard care text messages.


Eligibility criteria: Inclusion Criteria:

* 1) call the Quitline requesting assistance with quitting smoking, 2) be 18+ years old, 3) speak English, 4) have a verified New York address, and 5) opt into the standard Quitline texting protocol.

Exclusion Criteria:

-

Primary outcomes:
measure: survey of smoking status
timeFrame: Week 30
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical University of South Carolina
name: Benjamin Toll, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00937742: The Effect of Processed Tomato Products on CVD Risks
Official title: The Effect of Processed Tomatoes on Endothelium- and Platelet- Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Disease
Keywords: cardiovascular disease
Lycopene
Tomato
Lead sponsor: Penn State University
Sponsor class: OTHER
Collaborators: name: Tomato Products Wellness Council
First posted: 2009-07-13
Enrollment: 32
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary working hypothesis is that consuming processed tomatoes frequently/daily will favorably improve endothelium and platelet function disease-risk biomarker profiles in adult men and women compared to consuming no or relatively low amounts of processed tomatoes.


Eligibility criteria: Inclusion Criteria:

men and women (\>21 \<70 years) nonsmokers, with a body mass index (BMI) ranging of 25 to 35 kg/m2, BP \< or = 140/90 mmHg

Exclusion Criteria:

1. Total cholesterol (TC) is greater than 300 mg/dL;
2. Fasting triglyceride is greater than 300 mg/dL;
3. LDL cholesterol (LDL-C) is greater than 180 mg/dL;
4. Female subjects who are pregnant or lactating;
5. Subjects who are actively losing weight or trying to lose weight;
6. Subjects with known allergy or intolerance to tomato products;
7. taking any medications that would interfere with outcomes of the study, ie. lipid lowering medications, anti-inflammatory drugs, dietary supplements, such as fish oil or evening primrose;
8. subjects' with documented atherosclerotic disease, inflammatory disease, diabetes mellitus, uncontrolled hypertension (\>=140/90 mm Hg - ok if controlled below this limit with medication), or other systemic diseases;
9. subjects with low hematological counts as determined by \>or \<15% the upper or lower cut-off values of normal established for the lab;
10. Smokers. -

Primary outcomes:
measure: Platelet and monocyte function/activity
timeFrame: Baseline and end of intervention phase (week 6)
measure: Vascular function
timeFrame: Baseline and end of intervention phase (week 6)
Secondary outcomes:
measure: Lipids
timeFrame: Baseline and end of intervention phase (week 6)
measure: Insulin/Glucose
timeFrame: Baseline and end of intervention phase (week 6)
measure: Inflammatory Markers
timeFrame: Baseline and end of intervention phase (week 6)
Other outcomes:
Locations:
city: University Park
country: United States
facility: Penn State University
state: Pennsylvania
Study officials:
affiliation: Penn State University
name: Penny M Kris-Etherton, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01694342: Telomere Parameters in Patients With Nonalcoholic Fatty Liver
Official title: Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: FATTY LIVER
NO MALIGNANCY
NO DECOMPENSATED ILLNESS
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2012-09-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals - over 18 years old that were diagnosed with nonalcoholic fatty liver and are on follow-up in our liver unit

Brief summary: Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.

Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group \[20\] and others \[21\]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.

Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability \[3\]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.


Eligibility criteria: Inclusion Criteria:

* age over 18
* diagnosis of fatty liver

Exclusion Criteria:

* no malignancy
* no eligible to sign the consent paper

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kefar Saba
country: Israel
facility: Meir Hospital
Study officials:
References: